دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 30,000,000 تومان- قیمت ویژه : 8,250,000تومان
دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 3,000,000 تومان- قیمت ویژه : 1,250,000تومان
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
doi : 10.1016/S0140-6736(24)01919-6
Volume 404, Issue 10459, 28 September–4 October 2024, Pages 1174-1176
Improved survival for patients with lung cancer treated with perioperative immunotherapy
Long-term ill health in sepsis survivors: an ignored health-care challenge?
Fixing systems not fathersSarah Blaffer Hrdy , Father Time: A Natural History of Men and Babies, Princeton University Press (2024), p. 432, $29·95, £25·00, ISBN: 9780691238777
Antibody titres after vaccination: a missing key to rabies control
Childhood health and nutrition challenges in Sudan's conflict zones
The Lancet Countdown on health and climate change: representation matters
The Lancet Countdown on health and climate change: representation matters – Authors' reply
The Lancet Countdown on health and climate change: competing interests and optimism bias
The Lancet Countdown on health and climate change: competing interests and optimism bias
The Lancet Countdown on health and climate change: competing interests and optimism bias – Authors' reply
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Bone marrow necrosis and hyperinflammation after treatment with inotuzumab ozogamicin for B-cell acute lymphoblastic leukaemia
